Cancer Microbiome Targeting Emerging Drug Developers
Microbiome is an emerging player in cancer drug development. Recent research findings elicit varied roles of human gut microbiome, both...
Antibody Drug Conjugates
Antibody Drug Conjugates (ADCs) are therapeutic entities with monoclonal antibody (mAb) backbone linked to cytotoxic drugs and are designed to...
Oncolytic Viruses
Oncolytic Viruses (OVs) based therapies uses natural or genetically modified viruses to specifically infect and lyse cancer cells but does not...
[mc4wp_form]
Big Pharma Oncology Insights
No Content Available
Bispecific Antibodies
Bispecific (bsAbs) & Multispecific antibodies are a diverse family of antibody constructs that recognize two or more epitopes. These candidates...
Cancer Targeting Cellular Therapies
Cell Therapies constitutes the largest number of agents in oncology drug development, with currently more than 2000+ Active Cancer Targeting...
Serine/Theonine Kinase Inhibitors
. SERINE / THEONINE KINASE INHIBITORS 1. BRAF/MEK/ERK Inhibitors 2. CDK Inhibitors 3. PI3K/AKT/mTOR Inhibitors Check Also KINASE INHIBITORS -...
Non Receptor Tyrosine Kinase Inhibitors
. NON-RECEPTOR TYROSINE KINASE INHIBITORS 1. Bcr-Abl1 Inhibitors 2. JAK Inhibitors 3. BTK Inhibitors Check Also KINASE INHIBITORS - An...
Receptor Tyrosine Kinase Inhibitors
Protein kinases are the enzymes that catalyzes the transfer of γ-phosphate group from ATP to protein residues containing hydroxyl groups...
Get a year of access for Premium Content
Join our Premium Membership and unlock all content for unlimited access.
Popular Posts
Mapping Bio-Innovations
updated.. easy.. precise... complete...
Presenting filtered comprehensive information. Gain more insights on emerging bio-business, frame strategies, grow faster & better connect with biological science community.
LEARN MORE »
